145 related articles for article (PubMed ID: 9755720)
1. Targeting hypoxia with a new generation of indolequinones.
Jaffar M; Naylor MA; Robertson N; Stratford IJ
Anticancer Drug Des; 1998 Sep; 13(6):593-609. PubMed ID: 9755720
[TBL] [Abstract][Full Text] [Related]
2. Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia.
Everett SA; Naylor MA; Nolan J; Patel KB; Wardman P
Anticancer Drug Des; 1998 Sep; 13(6):635-53. PubMed ID: 9755722
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships.
Phillips RM; Naylor MA; Jaffar M; Doughty SW; Everett SA; Breen AG; Choudry GA; Stratford IJ
J Med Chem; 1999 Oct; 42(20):4071-80. PubMed ID: 10514277
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?
Robertson N; Stratford IJ; Houlbrook S; Carmichael J; Adams GE
Biochem Pharmacol; 1992 Aug; 44(3):409-12. PubMed ID: 1510692
[TBL] [Abstract][Full Text] [Related]
5. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
6. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
7. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
8. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.
McNally VA; Patterson AV; Williams KJ; Cowen RL; Stratford IJ; Jaffar M
Curr Pharm Des; 2002; 8(15):1319-33. PubMed ID: 12052210
[TBL] [Abstract][Full Text] [Related]
10. Cyclopropyl indolequinones: mechanistic probes for bioreductive anticancer drug action.
Moody CJ; Norton CL; Slawin AM; Taylor S
Anticancer Drug Des; 1998 Sep; 13(6):611-34. PubMed ID: 9755721
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
12. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.
Naylor MA; Swann E; Everett SA; Jaffar M; Nolan J; Robertson N; Lockyer SD; Patel KB; Dennis MF; Stratford MR; Wardman P; Adams GE; Moody CJ; Stratford IJ
J Med Chem; 1998 Jul; 41(15):2720-31. PubMed ID: 9667963
[TBL] [Abstract][Full Text] [Related]
13. New EORTC compounds.
Lelieveld P; Hendriks HR
Cancer Treat Rev; 1990 Sep; 17(2-3):119-25. PubMed ID: 2272028
[No Abstract] [Full Text] [Related]
14. Novel bioreductive anticancer agents based on indolequinones.
Moody CJ; Swann E
Farmaco; 1997 May; 52(5):271-9. PubMed ID: 9273997
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
16. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins.
Walton MI; Sugget N; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):643-7. PubMed ID: 1544831
[TBL] [Abstract][Full Text] [Related]
17. 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro.
Jaffar M; Naylor MA; Robertson N; Lockyer SD; Phillips RM; Everett SA; Adams GE; Stratford IJ
Anticancer Drug Des; 1998 Mar; 13(2):105-23. PubMed ID: 9524554
[TBL] [Abstract][Full Text] [Related]
18. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems.
Boruah RC; Skibo EB
J Med Chem; 1994 May; 37(11):1625-31. PubMed ID: 8201596
[TBL] [Abstract][Full Text] [Related]
20. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase.
Phillips RM
Biochem Pharmacol; 1996 Dec; 52(11):1711-8. PubMed ID: 8986133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
